P. Robbins

Oncology · Science · 2001–2018

A researcher in the Science corpus: 15 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Oncology — 106 citations into it; #1,387 of 1,698 by trust here, #129 by citations
• Immunology — 84 citations into it; #1,756 of 2,160 by trust here, #210 by citations

Whom P. Robbins trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Dudley
2. S. Rosenberg
3. R. Morgan
4. Jie Yang

Who trusts P. Robbins overall

1. S. Rosenberg
2. D. Thommen
3. A. Schietinger
4. Ton N. Schumacher
5. W. Zou
6. D. Mittal
7. Wendell A. Lim
8. C. June
9. M. Philip
10. Padmanee Sharma

Papers from P. Robbins's perspective

Ordered by how strongly the researchers P. Robbins trusts endorse each paper. Same corpus, a different order for every researcher.

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
4. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
5. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (Nature Medicine)
6. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (Journal of Clinical Oncology)
7. IL-2: The First Effective Immunotherapy for Human Cancer (Journal of Immunology)
8. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (Blood)
9. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (Science Translational Medicine)
10. Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)

Their papers

• Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (2013) — 1,116 citations
• Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013) — 1,094 citations
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
• Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018) — 708 citations
• T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer (2016) — 1,181 citations
• Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients (2016) — 809 citations
• Immunogenicity of somatic mutations in human gastrointestinal cancers (2015) — 702 citations
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. (2014) — 994 citations
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014) — 728 citations
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer (2014) — 1,637 citations
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011) — 1,972 citations
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) — 813 citations
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008) — 1,357 citations
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) — 3,012 citations
• A listing of human tumor antigens recognized by T cells (2001) — 810 citations